Two cholesterol drugs still taken by millions of Americans are the subject of concern for a second time, according to a new study.
In the study involving about 360 people, Zetia failed to shrink buildups in artery walls while a rival drug, Niaspan, did so significantly.
Ultrasound images of neck arteries showed that Niaspan shrank buildups by about 2 percent, while Zetia had no effect on this even though it lowered bad cholesterol as expected. The results were published by the New England Journal of Medicine.
Last year, a large study suggested that the combo pill Vytorin, which combines Zetia with a statin, was no more effective than Zocor alone, a statin now available as a cheap generic.
Niaspan is a slow-release version of niacin, a type of B vitamin. Both Zetia and Vytorin are sold by Merck & Co. Niaspan is made by Abbott Laboratories, which sponsored the latest study.
Merck says it stands behind its drugs, which accounted for billions in sales last year.
Copyright 2015 by The Associated Press. All Rights Reserved.